Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 195 of 195 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/19/22
End: 09/30/37
Due: 09/30/38
Phase: N/A
Priority: Normal
Start: 10/31/96
End: 08/31/10
Due: 08/31/11
Phase: N/A
Priority: Normal
Start: 10/31/98
End: 01/31/11
Due: 01/31/12
Phase: N/A
Priority: Normal
Start: 09/05/22
End: 04/15/29
Due: 04/15/30
Phase: N/A
Priority: Normal
Start: 10/01/21
End: 09/30/25
Due: 09/30/26
Phase: N/A
Priority: Normal
Start: 10/31/05
End: 08/31/12
Due: 08/31/13
Phase: N/A
Priority: Normal
Start: 06/30/16
End: 10/09/19
Due: 10/09/20
Phase: N/A
Priority: Normal
Start: 10/19/23
End: 06/30/30
Due: 06/30/31
Phase: N/A
Priority: Normal
Start: 10/18/18
End: 11/30/30
Due: 11/30/31
Phase: N/A
Priority: Normal
Start: 09/05/07
End: 04/30/13
Due: 04/30/14
Phase: N/A
Priority: Normal
Start: 06/18/21
End: 04/30/26
Due: 04/30/27
Phase: N/A
Priority: Normal
Start: 07/18/24
End: 06/30/28
Due: 06/30/29
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.
Phase: N/A
Priority: Normal
Start: 10/28/20
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 04/26/11
End: 05/14/27
Due: 05/14/28
Phase: N/A
Priority: Normal
Start: 04/30/99
End: 06/30/08
Due: 06/30/09
Phase: N/A
Priority: Normal
Start: 05/31/19
End: 02/28/21
Due: 02/28/22
Phase: N/A
Priority: Normal
Start: 09/21/17
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 04/01/17
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 07/25/18
End: 11/15/21
Due: 11/15/22
Phase: N/A
Priority: Normal
Start: 07/05/17
End: 12/14/23
Due: 12/14/24